Illumina, Inc. (NASDAQ:ILMN) price target set to $370.00 by Bank of America

ME Staff
-
0

Analyst Ratings For Illumina, Inc. (NASDAQ:ILMN)

Today, Bank of America set its price target on Illumina, Inc. (NASDAQ:ILMN) to $370.00 per share.

There are 14 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on Illumina, Inc. (NASDAQ:ILMN) is Buy with a consensus target price of $288.6875 per share, a potential 7.02% downside.

Some recent analyst ratings include

  • 7/31/2018-Piper Jaffray Companies Reiterated Rating of Positive .
  • 7/27/2018-Canaccord Genuity Reiterated Rating of Buy .

Recent Insider Trading Activity For Illumina, Inc. (NASDAQ:ILMN)
Illumina, Inc. (NASDAQ:ILMN) has insider ownership of 0.54% and institutional ownership of 90.03%.

  • On 7/23/2018 Robert S Epstein, Director, sold 500 with an average share price of $311.15 per share and the total transaction amounting to $155,575.00.
  • On 7/12/2018 Francis A Desouza, Insider, sold 3,300 with an average share price of $300.00 per share and the total transaction amounting to $990,000.00.
  • On 7/10/2018 Mostafa Ronaghi, SVP, sold 7,500 with an average share price of $288.89 per share and the total transaction amounting to $2,166,675.00.
  • On 7/2/2018 Francis A Desouza, CEO, sold 2,100 with an average share price of $276.14 per share and the total transaction amounting to $579,894.00.
  • On 6/21/2018 Robert S Epstein, Director, sold 500 with an average share price of $288.45 per share and the total transaction amounting to $144,225.00.
  • On 6/11/2018 Marc Stapley, EVP, sold 1,446 with an average share price of $285.18 per share and the total transaction amounting to $412,370.28.
  • On 6/11/2018 Mostafa Ronaghi, SVP, sold 10,500 with an average share price of $284.83 per share and the total transaction amounting to $2,990,715.00.

About Illumina, Inc. (NASDAQ:ILMN)
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, agrigenomics, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. The company has a strategic partnership with Loxo Oncology, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and strategic collaboration with Bristol-Myers Squibb Company. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

Recent Trading Activity for Illumina, Inc. (NASDAQ:ILMN)
Shares of Illumina, Inc. closed the previous trading session at 314.67 up +25.43 8.79% with 313.11 shares trading hands.